COVID-19 Clinical Trial
Official title:
A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection
NCT number | NCT04459702 |
Other study ID # | PRG-043 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 2020 |
Est. completion date | December 2021 |
Verified date | April 2021 |
Source | ProgenaBiome |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2021 |
Est. primary completion date | July 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study 2. Healthy, ambulant male or female subjects 18 years of age to 65 years of age 3. Positive test for COVID-19 by RT-PCR at screening 4. Subjects must agree to practice at least one highly effective method of birth control for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized) 5. Subjects must agree they will do their best to attend the treatment facility daily for 10 days Exclusion Criteria: 1. Refusal to sign informed consent form 2. Negative test for COVID-19 by RT-PCR at screening 3. Severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 38 degrees; pleuritic pain, or frequent cough. 4. Known drug allergy to any of the investigational medications 5. Currently taking medication with known drug interactions with investigational medications (listed in appendix) 6. Prescription or other antiviral medications 7. Any comorbidities which constitute health risk for the subject 8. Pregnant or lactating females; 9. weight < 110lb; 10. porphyria 11. established retinal disease 12. Inability to attend daily for 10 days 13. Any contraindications for treatment with hydroxychloroquine 1. Hypoglycemia 2. Known G6PD deficiency 3. Porphyria 4. Anemia 5. Neutropenia 6. Alcoholism 7. Myasthenia gravis 8. Skeletal muscle disorders 9. Maculopathy 10. Changes in visual field 11. Liver disease 12. Psoriasis 13. History of QT >500msec 14. History of torsades de pointes 14. Anemia from pyruvate kinase and G6PD deficiencies 15. Abnormal EKG with QT prolongation acquired or from birth 16. History of jaundice or high fevers prior to developing COVID-19 17. Treatment with any of the medications listed in Appendix II 18. Treatment with any anti-epileptic medication 19. Treatment with any other drug not listed that affects the QT interval |
Country | Name | City | State |
---|---|---|---|
United States | ProgenaBiome | Ventura | California |
Lead Sponsor | Collaborator |
---|---|
ProgenaBiome | Big Corona Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores | Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk. | 6 months | |
Primary | Efficacy of Treatment by Time to Non-Infectivity | Time to non-infectivity as measured by PCR testing | 10 days | |
Secondary | Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores | Patient symptoms will be recorded using the NEWS system, which rates patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk. | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores. | Patient symptoms will be recorded using the NEWS system, which rates patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk. | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Complete Blood Count | Changes in blood parameters measured in a Complete Blood Count (CBC). | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Complete Blood Count | Changes in blood parameters measured in a Complete Metabolic Panel. | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel -Albumin | Changes in serum albumin levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin | Changes in serum albumin levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio | Changes in serum albumin/globulin ratio | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio | Changes in serum albumin/globulin ratio | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase | Changes in serum alkaline phosphatase levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase | Changes in serum alkaline phosphatase levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - AST | Changes in serum AST levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - AST | Changes in serum AST levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT | Changes in serum ALT levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel ALT | Changes in serum ALT levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio | Changes in serum BUN/Creatinine Ratio | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio | Changes in serum BUN/Creatinine Ratio | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN | Changes in serum Blood Urea Nitrogen levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - BUN | Changes in serum Blood Urea Nitrogen levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Calcium | Changes in serum calcium levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium | Changes in serum calcium levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide | Changes in serum carbon dioxide levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide | Changes in serum carbon dioxide levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Chloride | Changes in serum chloride levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride | Changes in serum chloride levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine | Changes in serum creatinine levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine | Changes in serum creatinine levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Globulin | Changes in serum globulin levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin | Changes in serum globulin levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose | Changes in blood glucose levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Glucose | Changes in blood glucose levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Potassium | Changes in blood potassium levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium | Changes in blood potassium levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin | Changes in serum total bilirubin levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin | Changes in serum total bilirubin levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein | Changes in serum total protein levels | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein | Changes in serum total protein levels | 6 months | |
Secondary | Safety of Dual Therapy as Measured by Treatment Related SAE | Presence or absence of treatment related serious adverse events Grade III or higher | 6 months | |
Secondary | Safety of Quadruple Therapy as Measured by Treatment Related SAE | Presence or absence of treatment related serious adverse events Grade III or higher | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|